These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34861398)

  • 1. High-dose gatifloxacin-based shorter treatment regimens for MDR/RR-TB.
    Nie Q; Tao L; Li Y; Chen N; Chen H; Zhou Y; Wang Y; Chen H; Tang Q; Wang X; Huang C; Yang C
    Int J Infect Dis; 2022 Feb; 115():142-148. PubMed ID: 34861398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
    Kuaban C; Noeske J; Rieder HL; Aït-Khaled N; Abena Foe JL; Trébucq A
    Int J Tuberc Lung Dis; 2015 May; 19(5):517-24. PubMed ID: 25868018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis.
    Olliaro PL; Merle C; Mthiyane T; Bah B; Kassa F; Amukoye E; N Diaye A; Perronne C; Lienhardt C; McIlleron H; Fielding K
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Shorter Treatment Regimen in Multidrug-Resistant Tuberculosis Patients in Pakistan: A Multicenter Retrospective Record Review.
    Wahid A; Ahmad N; Ghafoor A; Latif A; Saleem F; Khan S; Atif M; Iqbal Q
    Am J Trop Med Hyg; 2021 Mar; 104(5):1784-1791. PubMed ID: 33724924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.
    Ali AM; Radtke KK; Hesseling AC; Winckler J; Schaaf HS; Draper HR; Solans BP; van der Laan L; Hughes J; Fourie B; Nielsen J; Garcia-Prats AJ; Savic RM
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0144822. PubMed ID: 37358463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study.
    Li R; Ma JB; Yang H; Yang H; Yang XJ; Wu YQ; Ren F
    Microbiol Spectr; 2023 Aug; 11(4):e0104823. PubMed ID: 37310268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.
    Ahmad Khan F; Salim MAH; du Cros P; Casas EC; Khamraev A; Sikhondze W; Benedetti A; Bastos M; Lan Z; Jaramillo E; Falzon D; Menzies D
    Eur Respir J; 2017 Jul; 50(1):. PubMed ID: 28751411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries.
    Trébucq A; Schwoebel V; Kashongwe Z; Bakayoko A; Kuaban C; Noeske J; Hassane S; Souleymane B; Piubello A; Ciza F; Fikouma V; Gasana M; Ouedraogo M; Gninafon M; Van Deun A; Cirillo DM; Koura KG; Rieder HL
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):17-25. PubMed ID: 29149917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Short-term Regimen for Multidrug-resistant Tuberculosis Treatment: A Systematic Review of Cohort Studies.
    Mahardani PN; Wati DK; Siloam A; Savitri NPA; Manggala AK
    Oman Med J; 2022 Jan; 37(1):e337. PubMed ID: 35211341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB.
    Van Deun A; Decroo T; Kuaban C; Noeske J; Piubello A; Aung KJM; Rieder HL
    Int J Tuberc Lung Dis; 2019 Sep; 23(9):965-971. PubMed ID: 31615602
    [No Abstract]   [Full Text] [Related]  

  • 13. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
    Chiang CY; Lin CJ
    Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
    Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB
    Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shorter regimens improved treatment outcomes of multidrug-resistant tuberculosis patients in Tanzania in 2018 cohort.
    Mleoh L; Mziray SR; Tsere D; Koppelaar I; Mulder C; Lyakurwa D
    Trop Med Int Health; 2023 May; 28(5):357-366. PubMed ID: 36864011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis.
    Van Deun A; Maug AK; Salim MA; Das PK; Sarker MR; Daru P; Rieder HL
    Am J Respir Crit Care Med; 2010 Sep; 182(5):684-92. PubMed ID: 20442432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study.
    Brust JCM; Gandhi NR; Wasserman S; Maartens G; Omar SV; Ismail NA; Campbell A; Joseph L; Hahn A; Allana S; Hernandez-Romieu AC; Zhang C; Mlisana K; Viljoen CA; Zalta B; Ebrahim I; Franczek M; Master I; Ramangoaela L; Te Riele J; Meintjes G
    Clin Infect Dis; 2021 Dec; 73(11):2083-2092. PubMed ID: 33882121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger.
    Harouna SH; Ortuno-Gutierrez N; Souleymane MB; Kizito W; Morou S; Boukary I; Zolfo M; Benedetti G; Piubello A
    Int J Tuberc Lung Dis; 2019 May; 23(5):625-630. PubMed ID: 31097073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses.
    Piubello A; Harouna SH; Souleymane MB; Boukary I; Morou S; Daouda M; Hanki Y; Van Deun A
    Int J Tuberc Lung Dis; 2014 Oct; 18(10):1188-94. PubMed ID: 25216832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study.
    Hassane-Harouna S; Cherif GF; Ortuno-Gutierrez N; Cisse D; Camara LM; Diallo BD; Camara S; Bangoura AM; Lynen L; Decroo T
    PLoS One; 2020; 15(8):e0237355. PubMed ID: 32776969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.